Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
- Conditions
- Overactive BladderUrinary Bladder OveractiveUrgency IncontinenceUrinary Bladder Diseases\Urologic Diseases
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1829
- Registration Number
- NCT02045862
- Locations
- 🇺🇸
Site US10133, Los Angeles, California, United States
🇺🇸Site US10553, Lincoln, Nebraska, United States
🇺🇸Site US10148, Hialeah, Florida, United States
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
- Conditions
- Phase 1BioavailabilityHealthy Subjects
- Interventions
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 72
- Registration Number
- NCT02010944
- Locations
- 🇩🇪
Parexel, Berlin, Germany
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
- Conditions
- Neurogenic Detrusor OveractivityPediatric
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 23
- Registration Number
- NCT01981954
- Locations
- 🇰🇷
Site KR8201 Severance Hospital, Seoul, Korea, Republic of
🇵🇭Site PH6301 Philippines Children's Medical Center, Manila, Philippines
🇺🇸Site US1008 Pediatric Urology Associates, P.C., Tarrytown, New York, United States
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
- Conditions
- Urinary Bladder OveractiveUrinary Bladder Diseases\Urologic DiseasesOveractive BladderUrgency Incontinence
- Interventions
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 3527
- Registration Number
- NCT01972841
- Locations
- 🇩🇪
Site DE49034 LMU Muenchen, Munich, Germany
🇩🇪Site DE49001 Private Practice, Neustadt I. Sachsen, Germany
🇺🇸Site US10064 The Group for Women, Virginia Beach, Virginia, United States
A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin
- Conditions
- EC905PharmacokineticsHealthy Subjects
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 30
- Registration Number
- NCT01953887
- Locations
- 🇬🇧
Parexel, London, United Kingdom
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
- Conditions
- Urinary Bladder DiseasesUrinary Bladder OveractiveUrologic Diseases
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 2174
- Registration Number
- NCT01908829
- Locations
- 🇺🇸
Urology Center of Central Florida, Kissimmee, Florida, United States
🇺🇸Alliance Urology Specialists, Greensboro, North Carolina, United States
🇳🇴Site: 47005, Bekkestua, Norway
Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms
- Conditions
- Relieve of Ureteral Stent Symptoms
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 131
- Registration Number
- NCT01880619
- Locations
- 🇪🇬
Urology and Nephrology Center, Mansoura, Egypt
Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients
- Conditions
- Overactive Bladder Syndrome
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01876186
- Locations
- 🇨🇳
Department of Obstetrics & Gynecology, National Taiwan University Hospital, Taipei, Taiwan
Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women
- Conditions
- Overactive BladderPostmenopausal DisorderUrination Disorders
- Interventions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01833663
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 86
- Registration Number
- NCT01799902
- Locations
- 🇧🇪
H.Hart Roeselaere, Roeselaere, Belgium
🇧🇪Maria Middelares, Gent, Belgium
🇧🇪AZ Damiaan, Oostende, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.